Charles A. Read

Cyclophosphamide versus Placebo in Scleroderma Lung Disease

Donald P. Tashkin, Robert M. Elashoff, Philip J. Clements et al. · New England Journal of Medicine · 2006 · 1.7K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial

Donald P. Tashkin, Michael D. Roth, Philip J. Clements et al. · The Lancet Respiratory Medicine · 2016 · 1.1K citations

Medicine, Pharmacology, Pharmacotherapy +11

Effects of 1-Year Treatment with Cyclophosphamide on Outcomes at 2 Years in Scleroderma Lung Disease

Donald P. Tashkin, Robert M. Elashoff, Philip J. Clements et al. · American Journal of Respiratory and Critical Care Medicine · 2007 · 464 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +15

Adult Bronchoscopy Training

Armin Ernst, Momen M. Wahidi, Charles A. Read et al. · CHEST Journal · 2015 · 100 citations · Full text

Impact of oral cyclophosphamide on health‐related quality of life in patients with active scleroderma lung disease: Results from the scleroderma lung study

Dinesh Khanna, Xiaohong Yan, Donald P. Tashkin et al. · Arthritis & Rheumatism · 2007 · 96 citations · Full text

Pharmacy, Internal Medicine, Pharmacotherapy +16